case report aspiration during anesthesia semaglutide 2023 risk tops anesthesiologists' concerns for patients on GLP-1 medications » Department of Anesthesiology » College of Medicine » University of Florida Doctors warn some popular weight-loss

Start your 14 day free trial today

Findings In this large multicenter study of 37.1 million adults with type 2 diabetes across 14 databases in the collaborative Observational Health Data Sciences and Informatics (OHDSI) network, a small increase was identified in the relative incidence of NAION from exposure to semaglutide compared with nonexposure

Online accounted for a significant market share in 2023, and Hospital Pharmacies is expected to hold a dominant position in the forecast period owing to as it plays a critical role in ensuring that patients receiving inpatient care or undergoing medical procedures have uninterrupted access to GLP-1 receptor agonists

In contrast, no apparent symptoms or mortality were observed in the control group or in the treatment groups

However, genetic variation in how your body responds to GLP-1 signals can make natural production insufficient for meaningful results